Ezetimibe Prescribing Soars in the United States as Compared With Canada, According to New Study From Western University of Health Sciences, the Institute for Clinical Evaluative Sciences and Yale University

POMONA, Calif.--(BUSINESS WIRE)--Use of a controversial new cholesterol-lowering drug, ezetimibe (trade names: Zetia, Ezetrol, Vytorin), has increased in the United States, far beyond that seen in Canada, where direct-to-consumer advertising (DTCA) is prohibited and there is more government regulation of drug reimbursement in publicly-funded drug formularies. Worldwide sales for ezetimibe is estimated at $5 billion in 2007.